[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].

Abstract

17 patients with hyperlipoproteinemia of type 11 (9 type IIa and 8 type IIb), 4 with hyperlipoproteinemia of type IV and 1 with hyperlipoproteinemia of type V were treated for 4.6 +/- 0.7 months with the new lipid lowering agent bezafibrate in a dose of 200 mg three times daily. Bezafibrate markedly lowered total serum cholesterol and triglycerides and increased HDL-cholesterol in each of these types of hyperlipoproteinemia. These data suggest that bezafibrate may be effective in reducing the possibly atherogenic LDL- and VLDL-fractions while increasing the antiatherogenic HDL-fraction.

• Authors: G Noseda, C Fragiacomo, P Weidmann, C Bachmann
• Journal: Schweizerische medizinische Wochenschrift (Schweiz Med Wochenschr) Vol. 110 Issue 49 Pg. 1875-7 (Dec 06 1980) ISSN: 0036-7672 [Print] Switzerland
• Vernacular Title: Therapeutische Wirksamkeit von Bezafibrat bei Hyperlipoproteinämien verschiedenen Typs.
• PMID: 7455660 (Publication Type: English Abstract, Journal Article)

Chemical References

• Lipoproteins, HDL
• Triglycerides
• Clofibric Acid
• Cholesterol
• Clofibrate
• Bezafibrate

Topics

• Bezafibrate
• Cholesterol (blood)
• Clofibrate (analogs & derivatives)
• Clofibric Acid (analogs & derivatives, therapeutic use)
• Humans
• Hyperlipoproteinemia Type II (drug therapy)
• Hyperlipoproteinemia Type IV (drug therapy)
• Hyperlipoproteinemia Type V (drug therapy)
• Hyperlipoproteinemias (drug therapy)
• Lipoproteins, HDL (blood)
• Triglycerides (blood)